In this project, we will train a ChatGPT to provide real-time answers to questions related to the SIV for older adults in Hong Kong.
This study aims to evaluate the usability, acceptability, and preliminary effectiveness of the ChatGPT among 50 community-living people aged 65 years and above in Hong Kong.
The primary objectives are to evaluate the usability and acceptability (including the extent of usage and subjective experiences of behavioural, cognitive, and affective engagement) of the ChatGPT at the end of the 4-week intervention period (T1).
The secondary objectives are to evaluate the following conditions measured at T1, as compared to those measured at baseline (T0):
1. Self-reported uptake of SIV in the past month. 2. Changes in behavioural intention to receive SIV for the approaching flu season. 3. Changes in knowledge and attitudes related to SIV.
Aged ≥65 years;
Possession of a Hong Kong ID;
Able to speak and comprehend Cantonese;
Have a smartphone with internet access;
With diagnosis of cognitive impairment or dementia;
Either blindness or deafness;
With known contraindications to the SIV as indicated by the Hong Kong Centre for Health Protection
Single group
Access to a trained ChatGPT
BehavioralParticipants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.
Perceived usability
Perceived usability assessed by the validated Chinese version of the 10-item Perceived Usability Scale (SUS)
Extent of usage documented by the ChatGPT
Extent of usage documented by the ChatGPT
Subjective experiences related to behavioural, cognitive, and affective engagement
Subjective experiences related to behavioural, cognitive, and affective engagement measured by the validated Twente Engagement with eHealth Technologies Scale (TWEETS)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
